ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

ASCO Members asked To Help In Planning

August 26, 1988

BCDDP “Major Accomplishment” Described By ACS’ Holleb

July 21, 1978

In Brief: Pay raise Must Come From Intramural Funds, Not Extramural, Administration Says

May 9, 1980

Staff Advisory Boards To Be Formed; Three BSCs Proposed

August 11, 1995

Eight applications Received For NSABP chairman

September 9, 1994

SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.

April 30, 2004